The firms will validate histopathology biomarkers related to bladder cancer using clinical data and tissue samples captured during cystoscopy.

Under the repurchase program, the company may repurchase shares through open market purchases, in privately negotiated transactions, or by other means.

Last week, readers were most interested in a story about ASCO's decision not to recommend the use of Grail's MCED test in light of NHS trial data.

The test's new AI component is meant to help identify men who are at risk of having the severity of their tumor upgraded at ...

The companies will initially offer C2N's PrecivityAD test in Argentina, Chile, Colombia, Dominican Republic, Ecuador, Jamaica, Mexico, Uruguay, and Venezuela.

Under the agreement, NDT has an exclusive worldwide license for diagnostic use of a panel of nine antibodies to different tau protein forms.

NEW YORK – A new test from Abbott, developed in collaboration with the Mayo Clinic, uses a self-administered tampon to collect samples to test for endometrial cancer. The test is the fruition of about ...

The tissue-based next-generation sequencing assay analyzes 324 genes as well as genomic signatures including microsatellite instability and tumor mutational burden.

Proceeds will go toward obtaining US Food and Drug Administration approval for its products, for research and development work, and for general corporate purposes.

NEW YORK – Biotechnology company Toby said on Tuesday that it received breakthrough device designation from the US Food and Drug Administration for its urine-based Alzheimer's disease test. The test ...